Background: Schistosomiasis is a chronic parasitic disease primarily endemic to tropical and subtropical regions, posing significant challenges to public health and economic development. Despite progress in global control efforts, the disease continues to be a major public health concern in high-burden countries such as China, Brazil, and Nigeria. This study seeks to assess the effectiveness of schistosomiasis control measures in these countries and on a global scale.
Methods: To analyze and visualize the distribution of schistosomiasis burden, data from the Global Burden of Disease (GBD) database for 2021 covering 204 countries were utilized. Statistical information on fatalities and Disability-Adjusted Life Years (DALYs) related to schistosomiasis from 1990 to 2021 was extracted, encompassing global, African, Asian, and American regions, as well as specific data for the countries of China, Brazil, and Nigeria. The Bayesian Average Annual Percentage Change (BAPC) model was applied for forecasting trends. Decomposition analysis was performed to assess the contributions of various factors to changes in disease burden, and the Annual Average Percentage Change (AAPC) was calculated using the Joinpoint model.
Results: Data from the GBD database reveal that the burden of schistosomiasis-related diseases is predominantly concentrated in Africa, Asia, and South America. In 2021, schistosomiasis-related DALYs in China and Brazil ranked 5th and 8th globally, respectively, while fatalities ranked 5th and 6th. Notably, schistosomiasis in Nigeria causes the highest DALYs and deaths globally. From 1990 to 2021, the AAPC in the burden of schistosomiasis-related diseases was negative globally, as well as in Africa, Asia, the Americas, and key countries such as China, Brazil, and Nigeria, with China showing the most significant decline. Between 2017 and 2021, the AAPC remained negative, with Africa registering the lowest AAPC during this period. Decomposition analysis identified population size, growth, and aging as the primary drivers of the increasing disease burden. In contrast, improvements in epidemiological factors, including reductions in incidence, case fatality rates and disease severity, partially countered this trend. Projections indicate that by 2050, the global burden of schistosomiasis will gradually decline, with China and Nigeria expected to achieve the lowest infection rates. However, Brazil is expected to experience a relatively slower decline.
Conclusion: This study analyzes the global burden of schistosomiasis from 1990 to 2021, showing an overall declining trend. While significant progress has been made in control measures in countries such as China, Brazil, and Nigeria, Nigeria remains the most severely affected, with the highest global DALYs and death tolls attributed to schistosomiasis. Despite the overall decline in disease burden, factors such as population growth and aging continue to drive an increase in the burden. Projections indicate that by 2050, the global burden of schistosomiasis will continue to decrease, with China and Nigeria expected to see the largest reductions, while Brazil will experience a relatively slower decline. These findings underscore the need for sustained and targeted control measures in high-burden countries.
Clinical Trial Number: Clinical trial number: not applicable.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10096-025-05102-y | DOI Listing |
Oncotarget
March 2025
Worldwide Innovative Network (WIN) Association - WIN Consortium, Chevilly-Larue, France.
The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment. Minimizing treatment not expected to benefit, and toxicity-including financial and time-are important goals of modern oncology.
View Article and Find Full Text PDFCurr Opin Support Palliat Care
March 2025
Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
Purpose Of Review: Two widely validated health-related quality of life (HR-QoL) tools, specifically designed for patients with advanced cancer, are the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 15 Palliative Care (EORTC QLQ-C15-PAL) and the Functional Assessment of Chronic Illness Therapy-Palliative (FACIT-Pal-14). This systematic review aims to evaluate the use of EORTC QLQ-C15-PAL and FACIT-Pal-14 in prospective studies in patients with advanced cancer, focusing on study types, clinical settings, additional HR-QoL tools used, and completion rates.
Recent Findings: Sixty studies were included in the analysis.
Food Chem X
February 2025
Bioactivity & Applications Laboratory, Department of Biological Sciences, Faculty of Science and Engineering, University of Limerick, V94 T9PX Limerick, Ireland.
Blackcurrant press cake (BPC) anthocyanins were recovered using ultrasound-assisted extraction, and the optimal BPC extract was tested for its antioxidant capacity using chemical and biological assays and applied in a functional food model. Extraction at 400 W for 10 min followed by freeze-drying rendered an extract rich in polyphenols (47.83 mg GAE/g), where delphinidin-3-rutinoside, delphinidin-3-glucoside, cyanidin-3-rutinoside, and cyanidin-3-glucoside accounted for 75 % of total phenolics.
View Article and Find Full Text PDFCancer Cell
March 2025
Faculté de Médecine, Université Paris-Saclay, 94270 Kremlin-Bicêtre, France; Department of Radiation Oncology, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France; INSERM U1030, Radiothérapie Moléculaire et Innovations Thérapeutiques, Gustave Roussy Cancer Campus (GRCC), 94805 Villejuif, France.
The mechanisms governing the abscopal effects of local radiotherapy in cancer patients remain an open conundrum. Here, we show that off-target intestinal low-dose irradiation (ILDR) increases the clinical benefits of immune checkpoint inhibitors or chemotherapy in eight retrospective cohorts of cancer patients and in tumor-bearing mice. The abscopal effects of ILDR depend on dosimetry (≥1 and ≤3 Gy) and on the metabolic and immune host-microbiota interaction at baseline allowing CD8 T cell activation without exhaustion.
View Article and Find Full Text PDFPhytomedicine
March 2025
Department of Laboratory Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi Guizhou 563003, China; School of Laboratory Medicine, Zunyi Medical University, Zunyi Guizhou 563006, China. Electronic address:
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a super-resistant bacterium with strong pathogenicity, causing broad range of infections in various tissues. α-Hemolysin (Hla) is the main virulence factor of S. aureus.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!